Company intelligence
Coriolis Pharma
Science Driven Development and Analytical Support - From Early Development to Commercialization.
About Coriolis Pharma
Coriolis Pharma is a globally operating and science driven contract research and development organization (CRDO). We support drug product development of biopharmaceuticals, including gene and cell therapies and vaccines, from early development to commercialization. Our focus lies on formulation development, lyophilization technologies and analytics (GMP and non-GMP) for a wide range of products. As a privately held and independent company with an interdisciplinary team of highly skilled scientists and an expert scientific advisory board, we provide cutting-edge services and tailor-made solutions for our clients. We offer a large selection of services for all types of biopharmaceuticals, including proteins, peptides, peptides, nucleic acids, gene- and cell therapy products, vaccines and virus(-like) particles up to biosafety level S2.
Verified activity
Signals from Coriolis Pharma
3 published signals
Research & Knowledge
Coriolis Pharma demonstrated a systematic, data-driven formulation strategy that enabled a 40-50% viscosity reduction while maintaining stability, product quality, and compatibility with pre-filled syringes and autoinjectors.
Reported by Coriolis Pharma
Products & Services
Coriolis Pharma released a new Developability Decision Guide for Nucleic Acid Therapeutics to help identify key risks and critical quality attributes impacting commercial success.
Reported by Coriolis Pharma
Presence & Recognition
Coriolis Pharma is exhibiting at CPHI Worldwide 2026 at Booth 10G24 in Milan, Italy from October 6 to 8, 2026, featuring the Coriolis team led by Michael WIGGENHORN, Matthias Lucke, Jörg Müller, Anna Gebhardt, Eva Keilhauer, PhD, Anja Bürger, Abdelrahman Elsharkawy, Daniel Weinbuch, and Bettina von Klitzing-Stückle.
Reported by Coriolis Pharma